A Phase 2 Study of Ruxolitinib in People With T-Cell Large Granular Lymphocytic Leukemia


Full Title

A Phase II Study Evaluating the Efficacy of Ruxolitinib in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)


Researchers want to see if ruxolitinib works well as a treatment for T-cell large granular lymphocytic leukemia (T-LGLL). T-LGLL is a rare cancer of white blood cells called lymphocytes. The people in this study have T-LGLL that keeps growing even with treatment.

Ruxolitinib blocks certain proteins (namely, JAK proteins and STAT3) that play a role in cancer growth. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have T-LGLL that came back or keeps growing even after treatment.
  • Have completed prior T-LGLL treatment at least 2 weeks before taking ruxolitinib.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Alison Moskowitz’s office at 646-608-3726.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID